GHRH analog with Drug Affinity Complex
CJC-1295 DAC
Cited range Long-acting
What it is
CJC-1295 with DAC adds a maleimidopropionic acid group that binds albumin, stretching GH-axis exposure across days. Early human PK work existed; development as a drug did not produce an approved product.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- A GHRH analog with DAC, a tag that makes it hang around for days instead of minutes.
- One or two injections a week is the usual cited pattern. It lifts the GH baseline more than a sharp pulse.
- People want easier GH support without daily shots. Tradeoff: less “natural pulse” shape, more water/tingle talk.
- Different from CJC-1295-no-DAC / Mod GRF, which is the short-acting cousin.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Sustained GHRH-receptor tone raises GH and IGF-1 more continuously than pulsatile no-DAC analogs. That is the pharmacologic reason people treat it as a weekly compound — and why flattening GH pulsatility is a standing criticism.
Possible side effects / caveats
Edema, joint pain, numbness, and IGF-1 elevation are the expected axis effects. Continuous GH tone is a different risk conversation than bedtime pulses. Confirm whether a vial is DAC or no-DAC before comparing numbers.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Cited range | 1–2 mg | Once or twice weekly | Dominant secondary-source window |